These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 27282189)

  • 1. The importance of predictive biomarkers in oncology drug development.
    Jørgensen JT
    Expert Rev Mol Diagn; 2016 Aug; 16(8):807-9. PubMed ID: 27282189
    [No Abstract]   [Full Text] [Related]  

  • 2. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
    Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
    EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The arrival of predictive biomarkers for monitoring therapy response to natural compounds in cancer drug discovery.
    El Bairi K; Atanasov AG; Amrani M; Afqir S
    Biomed Pharmacother; 2019 Jan; 109():2492-2498. PubMed ID: 30551510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy.
    Mok TSK; Crino L; Felip E; Salgia R; De Pas T; Tan DSW; Chow LQM
    Cancer Treat Rev; 2017 Apr; 55():181-189. PubMed ID: 28427013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategies in functional proteomics: Unveiling the pathways to precision oncology.
    Favicchio R; Thepaut C; Zhang H; Arends R; Stebbing J; Giamas G
    Cancer Lett; 2016 Nov; 382(1):86-94. PubMed ID: 26850375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib.
    Muller IB; De Langen AJ; Honeywell RJ; Giovannetti E; Peters GJ
    Expert Rev Anticancer Ther; 2016; 16(2):147-57. PubMed ID: 26654422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alectinib for treatment of ALK-positive non-small-cell lung cancer.
    Avrillon V; Pérol M
    Future Oncol; 2017 Feb; 13(4):321-335. PubMed ID: 27780368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer biomarkers: selecting the right drug for the right patient.
    Kelloff GJ; Sigman CC
    Nat Rev Drug Discov; 2012 Feb; 11(3):201-14. PubMed ID: 22322254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment.
    Schmidt KT; Chau CH; Price DK; Figg WD
    J Clin Pharmacol; 2016 Dec; 56(12):1484-1499. PubMed ID: 27197880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alectinib for the treatment of ALK-positive stage IV non-small cell lung cancer.
    Wong KM; Noonan S; O'Bryant C; Jimeno A
    Drugs Today (Barc); 2015 Mar; 51(3):161-70. PubMed ID: 25876560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The evolving potential of companion diagnostics.
    Khoury JD
    Scand J Clin Lab Invest Suppl; 2016; 245():S22-5. PubMed ID: 27433788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R.
    Wang Y; Chen S; Hu G; Wang J; Gou W; Zuo D; Gu Y; Gong P; Zhai X
    Eur J Med Chem; 2018 Jan; 143():123-136. PubMed ID: 29174809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Giving Up on Precision Oncology? Not So Fast!
    Warner JL
    Clin Transl Sci; 2017 May; 10(3):128-129. PubMed ID: 28146309
    [No Abstract]   [Full Text] [Related]  

  • 14. Challenges with biomarkers in cancer drug discovery and development.
    Ileana Dumbrava E; Meric-Bernstam F; Yap TA
    Expert Opin Drug Discov; 2018 Aug; 13(8):685-690. PubMed ID: 29792354
    [No Abstract]   [Full Text] [Related]  

  • 15. I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib.
    Ou SH; Greenbowe J; Khan ZU; Azada MC; Ross JS; Stevens PJ; Ali SM; Miller VA; Gitlitz B
    Lung Cancer; 2015 May; 88(2):231-4. PubMed ID: 25736571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel ALK inhibitors in clinical use and development.
    Iragavarapu C; Mustafa M; Akinleye A; Furqan M; Mittal V; Cang S; Liu D
    J Hematol Oncol; 2015 Feb; 8():17. PubMed ID: 25888090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Pursuit of Therapeutic Biomarkers with High-Throughput Cancer Cell Drug Screens.
    Williams SP; McDermott U
    Cell Chem Biol; 2017 Sep; 24(9):1066-1074. PubMed ID: 28736238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 Testing in Cancer: Challenges in Companion Diagnostic Development.
    Hansen AR; Siu LL
    JAMA Oncol; 2016 Jan; 2(1):15-6. PubMed ID: 26562503
    [No Abstract]   [Full Text] [Related]  

  • 19. Molecular targets in cancer therapy.
    Kummar S; Doroshow JH
    Expert Rev Anticancer Ther; 2013 Mar; 13(3):267-9. PubMed ID: 23477512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies for modern biomarker and drug development in oncology.
    Smith AD; Roda D; Yap TA
    J Hematol Oncol; 2014 Oct; 7():70. PubMed ID: 25277503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.